NEXTCURE, INC OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
NEXTCURE, INC (NXTC) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $0 for the 3-month period ending 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2026-08-18
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2026-06-30 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-09-30 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-06-30 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2024-09-30 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2023 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2022 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2021 was $0.00.
- NEXTCURE, INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2020 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 S-4 · filed 2026-08-18 | |||
| 2025-12-31 | $0.00 S-4 · filed 2026-08-18 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-18 | ||
| 2025-06-30 | $0.00 S-4 · filed 2026-08-18 | |||
| 2024-12-31 | $0.00 S-4 · filed 2026-08-18 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-11-02 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-11-04 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |